# Rice-derived Recombinant Human Serum Albumin for the Treatment of Hypoalbuminemia After Hepatectomy: A Prospective, Single-Arm, Exploratory Clinical Trial

> **NCT07634549** · PHASE4 · RECRUITING · sponsor: **Cheng Qi** · enrollment: 50 (estimated)

## Conditions studied

- Post-hepatectomy Hypoalbuminemia

## Interventions

- **DRUG:** Rice-derived recombinant human serum albumin (OsrHSA)

## Key facts

- **NCT ID:** NCT07634549
- **Lead sponsor:** Cheng Qi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2027-07-07
- **Final completion:** 2027-07-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634549, "Rice-derived Recombinant Human Serum Albumin for the Treatment of Hypoalbuminemia After Hepatectomy: A Prospective, Single-Arm, Exploratory Clinical Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07634549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*